Review article · 2025 · Open access

Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape

Ainara Salgado-Pascual, Sara Zalba, Juan José Lasarte, María J. Garrido

Advanced Drug Delivery Reviews, 229, 115760 · Published 12 December 2025 · DOI 10.1016/j.addr.2025.115760

Open full textCite this paper

In brief

“Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape” is a 2025 review article by Ainara Salgado-Pascual and 3 co-authors, published in Advanced Drug Delivery Reviews. OpenAlex counts 18 citations as of 17 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Advanced Drug Delivery Reviews.

Citations
18
Most cited in
2026 (18)
Field-weighted impact
0.81
References
182
Authors
4

Abstract

Pancreatic cancer, particularly ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal subtypes due to late diagnosis, the absence of early biomarkers, and the presence of a complex tumor microenvironment (TME). This TME is characterized by a dense desmoplastic stroma, hypovascularization, immunosuppression, and an acidic extracellular pH. All of these factors hinder the delivery and efficacy of conventional therapies, especially in advanced stages. Nanoparticles (NPs), including liposomes, polymeric micelles, albumin-bound particles and lipid nanoparticles, have emerged as a promising tool for overcoming TME barriers, and enhance drug delivery in tumor while minimizing systemic toxicity. NPs can exploit mechanisms such as the Enhanced Permeability and Retention (EPR) effect and active targeting. Clinically approved NPs such as Nab-Paclitaxel and liposomal Irinotecan have demonstrated improved pharmacokinetics and therapeutic benefits in PDAC. Furthermore, ongoing clinical trials are exploring novel NP-based strategies such as gene delivery, radiosensitization, immunomodulation and ferroptosis induction. Despite these promising advances, significant challenges remain, including poor tumor penetration, heterogeneity in EPR, and immune recognition of NPs leading to their clearance from bloodstream before reaching the tumor. Innovative solutions such as biomimetic coatings, stimuli-responsive systems and personalized formulations, are being evaluated to enhance NP performance. Standardization of NP characterization and data reporting are essential to accelerating clinical translation. The integration of artificial intelligence and machine learning could further optimize NP design and patient stratification. Overall, nanotechnology represents a crucial frontier of research for developing more effective and personalized pancreatic cancer treatments.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2025). Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. Advanced Drug Delivery Reviews, 229, 115760. https://doi.org/10.1016/j.addr.2025.115760

MLA 9

Salgado-Pascual, Ainara, et al. “Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape.” Advanced Drug Delivery Reviews, vol. 229, 2025, p. 115760. https://doi.org/10.1016/j.addr.2025.115760.

Chicago

Salgado-Pascual, Ainara, Sara Zalba, Juan José Lasarte, and María J. Garrido. 2025. “Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape.” Advanced Drug Delivery Reviews 229: 115760. https://doi.org/10.1016/j.addr.2025.115760.

Harvard

Salgado-Pascual, A. et al. (2025) ‘Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape’, Advanced Drug Delivery Reviews, 229, p. 115760. doi:10.1016/j.addr.2025.115760.

IEEE

A. Salgado-Pascual, S. Zalba, J. J. Lasarte, and M. J. Garrido, “Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape,” Advanced Drug Delivery Reviews, vol. 229, p. 115760, 2025, doi: 10.1016/j.addr.2025.115760.

BibTeX

@article{salgadopascual2025emerging,
  title     = {{Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape}},
  author    = {Salgado-Pascual, Ainara and Zalba, Sara and Lasarte, Juan José and Garrido, María J.},
  journal   = {Advanced Drug Delivery Reviews},
  year      = {2025},
  volume    = {229},
  pages     = {115760},
  doi       = {10.1016/j.addr.2025.115760},
  url       = {https://doi.org/10.1016/j.addr.2025.115760}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery

  • pancreatic ductal adenocarcinoma
  • nanoparticle drug delivery
  • tumor microenvironment
  • liposomes
  • polymeric micelles
  • lipid nanoparticles
  • enhanced permeability and retention effect
  • active targeting

Work with this paper

Most-cited papers in Materials Science

All highly cited Materials Science papers

Questions about this paper

How do I cite this paper in APA style?

Salgado-Pascual, A., Zalba, S., Lasarte, J. J., & Garrido, M. J. (2025). Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. Advanced Drug Delivery Reviews, 229, 115760. https://doi.org/10.1016/j.addr.2025.115760

How many times has this paper been cited?

18 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Advanced Drug Delivery Reviews: sign in and open the full text from this page.

Who wrote this paper?

Ainara Salgado-Pascual, Sara Zalba, Juan José Lasarte, María J. Garrido.

What is the DOI of this paper?

10.1016/j.addr.2025.115760, permanently at https://doi.org/10.1016/j.addr.2025.115760. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.